Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dover Corp (DOV) vs Stryker Corporation (SYK) Price & Performance

Dover CorpTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Dover Corp vs Stryker Corporation — how do they compare? Dover Corp trades at $189.03 (market cap $25.45B), while Stryker Corporation trades at $278.72 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 4.2× Dover Corp's market cap, and Stryker Corporation pays the higher dividend (1.27%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Stryker Corporation for 20 Days on average.

DOVSYK
Market Cap
$25.45B$106.24B
Volume
661,7582,982,001
Sector
IndustrialsHealth
52-Week High
$233.31$388.35
52-Week Low
$161.16$269.75
Typical Hold Time
73 Days20 Days
Enterprise Value
$26.95B$117.70B
Dividend Yield
1.11%1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dover Corp

Dover Corporation (DOV) trades at $188.29, down 1.87% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and healthy profitability (13.48% net margin, 14.98% ROE). Recent acquisitions of Cloeren and Leistung expand manufacturing capabilities, while analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential.

The outlook remains positive given Dover's Dividend King status, strategic acquisitions, and Wall Street support. Key risks include cyclical industrial exposure and recent negative cash flow trends. With no analyst sell ratings and technical indicators suggesting potential oversold conditions, the stock presents a compelling opportunity for long-term investors despite near-term bearish technical signals.

Stryker Corporation

Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.

Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DOV
100% Buy0% Sell
Avg holding period · 73 Days
SYK
1% Buy99% Sell
Avg holding period · 20 Days

Top news

Latest headlines on both assets

About Dover Corp

Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.

Read more on DOV →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →